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Abstract 
 Vaccines are weakened or mutated versions of the pathogens that invoke an immune 
response through controlled and targeted delivery. Live-attenuated and inactivated vaccines 
invoke an immediate and protective immune response but have higher risks in a subset of 
patients. Subunit vaccines are an antigenic part of the pathogen that can be paired with an 
adjuvant to invoke an effective immune response and cause less adverse reactions. Adjuvants are 
made of a wide variety of materials that aid in antigenic expression in the body, in hopes of 
providing protection.  
 Nanodiamonds have a 3D carbon structure that has highly tailorable surface chemistry to 
provide customization for interaction of antigens that would mimic an effect similar to a virus-
like particle. Here, the synthesis of modified nanodiamonds is further developed by chemical 
modifications into three derivatives: oxidized, acidified, and amine modified nanodiamonds. 
Each derivative was compositionally and morphologically characterized to understand their 
stability and binding capacity. The unmodified nanodiamonds were selected to be further 
characterized but with a vaccine called RiVax. RiVax is a mutated ricin protein that prevents 
ricin toxicity for up to four months, but greater longevity and immunity is desired. In in vivo 
release studies, RiVax adsorbed to the unmodified nanodiamonds had recognition of adsorbed 
ricin and significantly low recognition of soluble ricin, leading to a survival rate of 50% in mice. 
Overall, nanodiamonds did not improve the RiVax vaccine but has shown respectable 
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1. Introduction 
 Vaccines are biological preparations that help prevent infectious diseases by activating 
the immune system, which have eradicated many diseases such as smallpox and rinderpest.[1] 
Vaccines activate the immune system through controlled presentation of modified forms or 
components of infectious pathogens. Early vaccines used live-attenuated or inactivated versions 
of pathogens, which work well in developing both an immediate response and a protective long-
term immunity but pose some risk since severe reactions are sometimes observed in a subset of 
patients.[2]  There is no vaccination that is 100% effective, and a small percentage of vaccinated 
individuals will get the disease; however, this percentage is insignificant compared to individuals 
who are not vaccinated.  
 Some vaccine approaches, such as subunit vaccines, require additional components (e.g. 
adjuvants) to elicit a strong response to the native pathogen. Adjuvants are materials that 
enhance the immune response toward a specific antigen compared to the administration of 
antigen alone, and this way helps provide lasting protection. Figure 1 demonstrates how an 
Figure 1. Targeted lymph node drug delivery to enhance a humoral and cellular response. The antigen is taken through 
lymphatic delivery where the antigen is presented to T- cells by an antigen presenting cell. Two paths can be taken, B-cells that 
help produce an antigen specific antibody to defend against extracellular pathogens (humoral response) or T-cells that defend 
against intracellular pathogens (cellular response). This figure is used with the permission of copyright clearance from Elsevier.
 
2 
antigen, through lymphatic delivery, can cause an immune response via humoral and cellular 
routes of protection.[3,29] 
 As modern vaccine research moves forward, nanotechnology concepts are being applied 
to produce significant progress through improved delivery and immunogenicity.[4] 
Nanotechnology is the study of synthetic and organic materials on a scale of less than 100 
nanometers (nm), and the fabrication of new materials that exhibit unique properties not found in 
their bulk equivalents. Various applications of nanotechnology exist in medicine, electronics, 
environmental studies, and consumer goods. In medicine, nanotechnology has been widely 
applied as a form of drug delivery due to targeted specificity and tailorability.[5, 6] Of note, 
investigations of nanoparticles has involved their versatility and applicability towards poorly 
water-soluble drug delivery, therapeutic co-delivery modalities, improved drug bioavailability, 
and many other targeted drug delivery applications. The development of nanoparticles as a 
protein delivery platform is an attractive approach for implementing subunit vaccines. 
Nanoparticles can have similar dimensions to viruses and have the potential to emulate some 
properties of live-attenuated vaccines including maintaining efficacy without the risks associated 
with their live-attenuated and inactivated counterparts.[7] 
 Nanodiamonds’ chemical and structural properties make them a potential choice for 
establishing protection against toxic bioweapons, such as ricin. Ricin is a highly toxic, naturally 
produced protein comprised of two subunits; an A chain with cytotoxic effects and a B chain that 
binds to receptor moieties. Ricin poisoning halts protein synthesis by removing an adenine 
residue from the ribosomal RNA causing ribosomal production to decrease.[8] Immunization with 
RiVax, a modified form of the ricin subunit A, has shown some ability to provide short-term 
protection in murine models. An improved RiVax vaccine could protect those of high risk, such 
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as emergency first responders and military personnel, against ricin were it ever to be used as a 
biological weapon.[9]    
 In this study, characterization of various nanodiamond forms were explored to understand 
possible modifications that could be useful for various carbon-based nanoparticle applications 
toward vaccine adjuvency and subunit presentation. RiVax was used as a model protein antigen 




 The development of vaccines and their widespread implementation has nearly eradicated 
many deadly diseases such as polio, measles, mumps, and hepatitis A, preventing an estimated 
4.5 billion cases and protecting more than 100 million lives.[10, 11] Vaccines elicit protective 
immunity against pathogens, commonly microbes and viruses, by priming the immune system 
with a safe amount of pathogen prior to infection. Historically, vaccines have been administered 
using four common modalities: live-attenuated, whole killed, subunit and conjugated.[12] Live-
attenuated vaccines are a weakened version of the live pathogen and are very effective in 
conferring protective memory due to their nearly identical properties to those of the native 
pathogen. However, because these attenuated pathogens may replicate, there is a small 
possibility they can revert back to a pathogenic form and cause illness.[13] Whole killed vaccines 
are made by exposing the bacteria to high temperature or chemical stresses ultimately leading to 
pathogen death. These vaccines contain inactive pathogen, which produce an immune response 
but require multiple doses of the vaccine to reach the same protective efficacy as a live-
attenuated vaccine.[14] Of note, all vaccines that are not live-attenuated require a booster; the 
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initial vaccination primes the immune system and protective immunity develops after subsequent 
doses are complete. Subunit vaccines are composed of an immunogenic portion of a pathogen, 
containing one or several epitopes.[13] These modalities provide safer, more stable vaccines 
which are more easily manufactured, but rarely induce a strong immune response when 
administered alone.[9, 12] To improve a subunit vaccine’s protective capacity, conjugation of an 
adjuvant to the antigenic material creates an antigen-adjuvant delivery complex that often 
increases its immunogenicity. [15, 16] 
 
2.2. Immune System 
 There are two different parts of the immune system involved in developing a protective 
immune response: innate and adaptive. Innate immunity is the immediate, nonspecific response 
that occurs when an immunogen is detected in the body.[17] Adaptive immunity is the antigen-
specific response, which leads to long-lasting protective memory.[18] [19] 
When a foreign substance has breached the host’s barriers (e.g. skin, mucosa), the innate 
immune response begins a set of mechanisms that recognize and neutralize invaders. First, the 
complement system, which is made up of a variety of circulating proteins, binds to specific 
motifs on pathogens not normally found in the body. When bound, these protein-pathogen 
complexes trigger general and specific mechanisms that lead to recruitment of innate immune 
cells. These phagocytes and granulocytes (macrophages, neutrophils, etc.) break down the 
pathogen into potential antigens. Antigen-presenting cells (APCs), such as macrophages and 
dendritic cells, begin presenting specific fragments of the antigen, such as epitopes, on their 
surface. During this process, innate immune cells produce and secrete cytokines— soluble 
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proteins that influence and enhance the immune response— to recruit and activate more immune 
cells, including lymphocytes.[20]  
The lymphocytes that make up the adaptive immune system can be divided into cell-
mediated and humoral effector cells. The cell-mediated immune response recognizes and 
eliminates a cell that has an intracellular pathogen or genetic mutation, which can be recognized 
and cleared by CD8+ cytotoxic T-cells. In the humoral response, APCs present epitopes to helper 
T-cells, which interact with naïve B-cells. Naïve B-cells differentiate to produce an influx of 
mature B-cells, which can make antibodies specific to the epitope to which cell is primed. 
Mature B-cells can also differentiate into plasma cells and memory B-cells. Plasma cells produce 
and secrete an abundance of antigen specific antibody. A small subset of B-cells differentiates 
into memory B-cells, which occurs more easily when a combination of cytokines and other 
immune activities are present. Memory B-cells circulate in the blood until the pathogen is 
reencountered to initiate a direct line of defense for subsequent exposures to similar protein 
epitopes.[21]  
 
2.3. Adjuvant Technologies 
 Adjuvants help elicit a strong immune response towards antigens by engaging both the 
innate and adaptive immune systems. Some adjuvants used in approved clinical products or those 
currently being investigated in clinical trials include aluminum salts, oil emulsions, virus-like 
particles (VLPs), co-adjuvants, and nanoparticles.[22]  
 Aluminum salts are used in the majority of currently approved vaccines to enhance 
antibody production.[23] Aluminum based adjuvants, such as aluminum hydroxide or phosphate, 
were the first class of approved adjuvants used in 1926 for human vaccinations.[9, 24] The first 
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product approved that contained aluminum adjuvants was Aluminum salt precipitated diphtheria 
toxoid.[25, 26] Aluminum hydroxide gel (Alhydrogel or Alum) and Aluminum phosphate gel 
(Adju-Phos) are the two common forms of aluminum salt adjuvants used today, differing in 
crystallinity and surface charge.[9] Electrostatic interactions between antigens and aluminum 
adjuvants can create complexes that invoke an immune response. The nature of such interactions 
are a function of pH, ionic strength, and excipients.[27] However, such adjuvants often fail to 
induce a protective memory response.[24, 27] [28, 29] 
Oil emulsions are thermodynamically unstable heterogenous liquids consisting of two 
immiscible phases (typically oil and water), which are usually stabilized by the pressure of a 
detergent. A strong immune response is elicited by oil emulsions due to electrostatic and 
hydrophobic interactions between the oil emulsion and antigen.[9] Successful emulsion-based 
adjuvant approaches used currently in humans are MF59 and AS03, which are approved for use 
in an influenza vaccine.[25] However, some emulsions have unfavorable effects like necrosis, and 
consequently formulations must be highly optimized and characterized to reduce undesirable 
side effects.[25]  
Virus-like particles (VLPs) are adjuvants which aim to mimic the structure of a natural 
virus in hopes of generating a strong immune response.[30] VLPs have conformational epitopes 
on their surface presented in a patterned display similar to the native virus.[30] Gardasil is an 
approved VLP vaccine against the human papillomavirus that contains patterned recognition 
sequences that trigger the adaptive immune system, creating strong B-cell responses similar to 
the virus itself.[31] Since VLP scaffolds use self-forming recombinant proteins expressed from 
cell cultures, production and manufacturing can be relatively complex.[30] Epitopes also need to 
be relatively simple and well-defined to use in a VLP approach.[30, 32]  
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 Co-adjuvants are used to target and enhance the immune response to improve protection 
for some vaccines. Two different adjuvants are used to act as a delivery system and an immune 
potentiator.[33] Current research using in vitro profiling uses a combination adjuvants— Quillaja 
Saponaria (QS-21) and 3-deactylated monophosphoryl lipid A (3D-MPL) — in formulations to 
produce stronger humoral and cellular responses in mice and humans for malaria immunity.[34] 
QS-21 is used as an adjuvant delivery system to maximize APC uptake, while the other 3D-MPL 
acts as an immune potentiator to help activate induction pathways of adaptive immunity.[35] 
However, having two adjuvants with different physicochemical properties creates high expense 
and complexity in manufacturing.[35]  
 Nanoparticles can be used as a delivery device that are manipulated to adsorb or 
conjugate drugs onto their surfaces. Nanoparticles can provide high carrier capacity, 
incorporation of both hydrophobic and hydrophilic substances, and the flexibility to administer 
by multiple routes.[36] A variety of nanoparticle materials, such as metallic, lipid, polymeric and 
carbon-based, have been explored in the clinic and are considered safe.[36] Like aluminum salts, 
aluminum nanoparticles generally lack the ability to stimulate the cytotoxic T-lymphocytes to 
fully defend against a viral infection.[37] Lipid nanoparticles suffer from aggregation due to 
unpredictable gelation, which can cause inflammation, dependent on the route of 
administration.[37, 38] Polymeric nanoparticles are often designed to be biodegradable, permitting 
a controlled release of drug to the target site dependent upon crosslinking, porosity, and 
molecular weight of the material.[37] However,  polymeric nanoparticles tend to produce an 
uncontrollable biphasic release of the drug payload when no excipients are present.[37] Carbon-
based nanoparticles are considered an attractive alternative due to their affordability, 
adaptability, and low cytotoxicity.[39] 
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2.4. Nanodiamonds  
 Nanodiamonds are made of carbon atoms with sp3 orbitals, while graphite is composed of 
sp2 hybridized carbon atoms. Sp2 orbitals are prominent in graphene since the structure is a 2D 
hexagonal lattice sheet that is densely packed in layers, held together by π-π stacking.[40] 
Diamonds are made of tetrahedral sp3 orbitals that create a 3D cubic structure.[40] The internal 3D 
structure of nanodiamonds lack free electrons within the carbon network, creating immense 
strength compared to graphene. However, the nanodiamond surface contains a significant 
number of orbital valences due to graphene that acts as a multicharged radical donor, which 
allows the empty orbitals to be filled by free radicals from other chemical groups.[40] [41] 
Depending on the intended end-application, nanodiamonds are synthesized through chemical 
vapor deposition, high pressure and temperature, or detonation.[42] Chemical vapor depositions 
create films that are applicable as biosensor coatings, high pressure and temperature (HPHT) 
nanodiamonds are useful for bioimaging, and detonation creates aggregates/agglomerates that 
are useful for drug delivery and some bioimaging.[42] [43, 44] 
 For drug delivery, the nanodiamond’s surface can be easily manipulated for specific 
modifications.[42] Various functional groups, such as carboxylate, ketones, and aldehydes are 
present on the surface of nanodiamonds.[45] Currently nanodiamonds are being investigated for 
microbial detection, pathogen localization, biofilm modulation, growth inhibition, and as vaccine 
adjuvants.[46, 47] Because nanodiamonds have high surface adaptability, high stability, and low 




2.5. Development of a Protective Ricin Vaccine  
 Ricin is a protein toxin produced by the castor oil plant, composed of two subunits (A 
and B chain) and in its purified form is classified as a category B biological weapon. The A 
chain enables its enzymatic toxic effect, while the subunit B chain is a receptor binding moiety 
that facilitates entry into cells.[48, 49] Subunit A is a glycosidase that removes an adenine residue 
from an exposed ribosomal RNA loop translation.[8] The enzymatic subunit cleavage efficiency 
is higher than the reproduction rate of ribosomes in the cell, which results in the death of the 
cell.[8] The subunit B chain binds to surface β-D-glucopyranoside moieties of the target cell and 
inserts molecules into an intercellular compartment to initiate translocation across the cell 
membrane.[48, 49] There are a number of occurrences throughout history of ricin as a bioweapon; 
for example, the assassination of Georgi Markov in 1978, ricin traces on a letter sent to President 
Obama in 2013, or a more recent occurrence in 2015 when Mohammed Ali was convicted of 
possession. The need for a vaccine is clear, especially for military personnel if ricin is ever 
aerosolized in wartime.[48] [50] 
 RiVax is a vaccine candidate against the ricin toxin. RiVax is a shortened version of the 
subunit A-chain with point mutations to attenuate enzymatic activity and prevent vascular leak 
syndrome.[49] In phase I clinical trials, RiVax without adjuvants induced toxin neutralizing 
antibodies, like LE4, that lasted up to four months after the third inoculation.[51] However, an 
increase in longevity and magnitude of toxin neutralizing antibodies is highly desired.[51] LE4 is 
a monoclonal antibody that was made by injecting a mouse with RiVax, extracting B-cells from 
the mouse that express LE4, and fusing them with myeloma cells to create hybridoma cells.[52] 
The hybridoma cells were then purified and cultured to make the monoclonal antibodies, which 
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can be administered to a patient to help combat ricin toxicity and provide short term 
immunity.[52]  
The RiVax vaccine has been formulated with Alhydrogel, which was found to increase 
toxin neutralizing antibodies 10-fold in mouse studies, creating an additional pilot clinical IB 
trial.[53] High titers were found in total and neutralizing antibodies in half the patients, but all 
volunteers experienced one or more toxicities from the vaccine, including headaches and 
nausea.[53] RiVax has also been formulated with alpha-galactosylceramide, another potential 
vaccine adjuvant, which promoted a humoral response and protection from ricin in a murine 
model.[54] However, there was a delayed onset of toxin-neutralizing activity and a passive 
antibody study was not performed to assess the elevated antibody levels correlated to alpha-
galactosylceramide.[54] RiVax with an adjuvant elicits stronger toxin neutralizing antibodies, but 
toxicity and delayed onset are undesirable traits of current vaccination strategies. 
The characterization of nanodiamonds was extensively explored in this study to 
understand the modification options possible on their surface. RiVax was used as a model 
antigen to see the overall potential of nanodiamonds as a delivery/adjuvant system.  Lead 
candidates were applied to an in vivo mouse challenge model in an effort to improve upon the 
therapeutic profile of previous trials while maintaining protective capacity. 
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3. Materials and Methods  
3.1. Materials 
Monocrystalline synthetic diamond powder (MSY) was purchased from Microdiamant 
(Smithfield, PA). Nitric acid (Trace Metal Grade) and sulfuric acid (Certified ACS Plus) were 
purchased from Fisher Scientific (Pittsburgh, PA). Spermine (≥97%), N-hydroxysuccinimide 
(NHS), and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were purchased from Acros 
Organics-Fisher Scientific (Pittsburgh, PA). Bovine Serum Albumin (BSA) and lysozyme were 
both purchased from Sigma-Aldrich (St. Louis, MO). RiVax recombinant ricin toxin A-chain 
V76M/ Y80A (rRTA) was expressed and purified by the Middaugh laboratory (University of 
Kansas, Lawrence, KS).[48, 49, 55]  
 
3.2. Methods 
3.2.1. Nanodiamond Surface Modification  
 Three different types of nanodiamonds were created via surface modification: oxidized, 
acidified, and amine conjugated, along with the unmodified source of material. The raw MSY 
monocrystalline diamond powder are hereafter referred to as unmodified nanodiamonds (uNDs).  
 Oxidized nanodiamonds (oNDs) were created by spreading uNDs thinly in a petri dish 
and placing in a muffle furnace (Fisher Scientific, Miami, OK) at 590 °C for 24 hours under 
ambient air.[45] Over the heating period the powder changed from dark grey to white. [56] 
 Acidified nanodiamonds (aNDs) were developed by submerging the oNDs in a strong 
acidic bath (3:1 v/v H2SO4:HNO3) at 25 mg/ml in a sealed vessel and microwaved in a Mars 5 
Digestion Oven (CEM, Matthews, NC) for three hours at 350 °C. The acid solution was pipetted 
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off in a fume hood and the nanodiamonds were rinsed 3 times with 18 MΩ deionized water. The 
powder was then dried in a centrivap vacuum concentrator (Labconco, Kansas City, MO) at 
ambient temperature until completely dry.  
 The diamine nanodiamonds (dNDs) were synthesized by reacting the aNDs powder with 
spermine. aNDs were suspended in phosphate-buffered saline (PBS) at 1 mg/ml, which was 
made of 1 mM KH2PO4, 155 mM NaCl, and 3 mM Na2HPO4 in water at pH 7.4. NHS/EDC 
powders at a 1:1 volume ratio (8 mg/ml) were added to the aNDs suspension and mixed for 30 
minutes at room temperature. Spermine suspended in PBS at pH 7.4 (50 mg/ml) was added 
dropwise to the aND/NHS/EDC mixture over 60 minutes while stirring. The mixture was reacted 
overnight, about 15 hours, at ambient temperature and then dried by centrivap vacuum 
concentrator at ambient temperature. 
 All modified nanodiamonds were stored at room temperature, sealed, and protected from 
light. Unless otherwise noted in subsequent procedures, prior to analysis, derivatized NDs were 
suspended in a later specified buffer and dispersed using a Model 500 Sonic Dismembrator 
(Fisher Scientific, Pittsburgh, PA) equipped with a 0.75-inch solid horn tip at 20% amplitude for 
10 minutes. 
 
3.2.2. Nanodiamond Surface Characterization  
 The surface characteristics of each ND derivative were assessed using x-ray 
photoelectron spectroscopy (XPS), zeta potential, Fourier transform infrared (FTIR) and raman 
spectroscopy. XPS spectras were collected using a PHI 5000 VersaProbe II (Physical 
Electronics, Chanhassen, MN). Dry samples were loaded using nonconductive double-sided tape 
and two points analyzed for surface composition. Full composition analysis was set at 20 scans 
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for carbon and 10 scans for oxygen and nitrogen. Measurements were collected using Smartsoft 
and data analyzed using Multipak (PHI version 9.6.1).  
 ND zeta potential and raman spectra were measured using a ZetaSizer Nano (Malvern 
Panalytical, Westborough, MA). Each zeta potential sample was suspended at 0.01 mg/ml in 
deionized water and placed in a quartz cuvette provided by the instrument vendor. The 
instrument was held at 25 °C and zeta potential assessed using three acquisitions of 10-100 scans 
each. Data was analyzed using a Smoluchowski model. Raman spectra were collected in the 
same instrument using three acquisitions at 25 °C in the quartz window cuvette, but with samples 
suspended in 10 mM KCl at 0.1 mg/ml. Background spectra was subtracted and data analyzed 
using Helix Analyze (Malvern version 10.0).  
 The surface functionalization of the ND derivatives was analyzed using an IRAffinity-1 S 
FTIR Spectrometer (Shimadzu, Lenexa, KS). Each dry powder sample was placed onto the ATR 
mount with a sapphire crystal and gently compacted using the instrument stylus to improve the 
signal. Each sample was run in absorbance mode and spectra collected between 500 cm-1 and 
4000 cm-1 over 50 scans using IRsolution software (Shimadzu, version 1.2.0.). 
 
3.2.3. Nanodiamond Sizing and Morphology 
 The particle size of the nanodiamonds were measured by dynamic light scattering (DLS).  
Measurements were made using a DynaPro plate reader (Wyatt, Santa Barbara, CA) and 
analyzed by Dynamics Software (Wyatt, version 7.8.2). Each sample was placed in a Grainer 96-
well plate with a flat bottom and read in ten second acquisitions for five acquisitions.  
 Transmission electron microscopy (TEM) was performed with a FEI TECNAI F20 XT 
Field Emission Transmission Electron microscope (Fisher Scientific, Miami, OK) to analyze the 
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bulk chemistry of the nanodiamond derivatives. The microscope was equipped with a 200-kV 
electron source (Schottky field emitter) and a 0.25 nm TEM point resolution with a 
magnification range of 22x to 930,000x. Each nanodiamond derivative was suspended in ethanol 
at 1 mg/ml and 1 uL was placed onto a polymeric scaffold (Electron Microscopy Sciences, 
Hatfield, PA). Each sample was scanned in three separate structures created on the scaffolds to 
determine surface composition.   
 
3.2.4. Antigen to Nanodiamond Binding Isotherms 
 The binding isotherm assays used BSA or lysozyme as model proteins to determine the 
protein adsorption capacity of the uND, oND, aND, and dND powders. The nanodiamonds were 
suspended in 10 mM KCl at pH 4 and then mixed with BSA or lysozyme (0.06 to 4.0 mg/mL) 
for 30 minutes at 4 °C. The mixtures were centrifuged at 20 ºC for 4 minutes at 14,000 x g, and 
the supernatant removed and tested for protein concentration using a Synergy|H1 Microplate 
reader (BioTek) at 562 nm for BSA and 280 nm for lysozyme on Gen5 software (BioTek version 
3.03). Protein concentration was determined against a standard curve (protein at various 
concentrations). Supernatant protein concentration was taken as the unbound fraction and the 
remainder from total added taken as the bound fraction. Further studies utilized RiVax, which 
was added to nanodiamonds in 10 mM histidine, 10% (w/v) Sucrose, and 150 mM NaCl at pH 6 
and UV absorption measured at 280nm. For pH-dependent binding isotherms, the same steps 
were taken but the buffer pH adjusted to 2, 4, 6, 8, 10, and 12. 
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3.2.5. Nanodiamond Bound RiVax Structural Integrity 
 Tryptophan fluorescence melts were used to detect microenvironment polarity variance 
between RiVax and RiVax adsorbed to uNDs. Spectra optic and 310 nm optic were used for 
lifetime spectrum on a fluorescence plate reader (Fluorescence Innovations Inc., Minneapolis, 
MN). Each sample was centrifuged at 20 ºC for 4 minutes at 14,000 g and resuspended in fresh 
buffer (10 mM histidine, 10% Sucrose, and 150 mM NaCl at pH 6) to ensure completely bound 
protein. Then 10 µL of each sample was placed in a single well of a Greiner 364-well black, flat 
bottom plate (N=6) (Sigma Aldrich, St. Louis, MO) and all samples were then covered with 2 µL 
of silica oil to prevent the sample evaporation at high temperatures. Scans were taken at every 1 
°C from the interval of 10 °C to 90 °C using PR_v2 software (Fluorescence Innovations Inc. 
version 2.0). 
 
3.2.6. Nanodiamond Bound RiVax Antigenicity 
 Bio-Layer Interferometry (BLI) using an Octet Red 96 Interferometer (Pall Forte Bio, 
San Diego, CA) was used to measure the association rate of nanodiamond bound RiVax to a 
neutralizing antibody. The antibody, LE4, was diluted to 5 µg/ml in kinetic buffer made of 
0.02% (w/v) Tween 20, 0.2% (w/v) BSA, PBS, pH 7.4 and bound to an anti-mouse IgG Fc 
capture biosensor. Biosensors were regenerated using 10 mM glycine at pH 1.7 and stored per 
manufacturer instructions. Rivax was diluted to 31.25x the final concentration in 10 mM 
Histidine, 150 mM NaCl 10 % (w/v) sucrose at pH 6 or 10 mM Histidine and 10 % Sucrose at 
pH 6. uNDs at 2 mg/ml were then mixed with selected concentration of RiVax (50, 25, 12.5, and 
6.25 mg/ml) to yield a final concentration of 50, 25, 12.5, or 6.25 nM with respect to RiVax. 
Samples were then incubated for 30 minutes at 4 °C after which all protein was assumed bound 
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based on previous binding isotherm results. After mixing, the samples were diluted to 10x the 
final desired concentration with the buffers mentioned above and then each sample was diluted 
with the kinetics buffer to the final desired concentration. 
 
3.2.7. Nanodiamond Bound RiVax In-vivo Response 
 The mouse vaccination trials were conducted to evaluate the efficacy of the RiVax 
adsorbed to the uNDs compared to RiVax alone or formulated with other adjuvants. Since the 
concentration of RiVax for a mouse vaccine is low, the methodology was changed to permit 
complete binding of the antigen at low concentration.[48, 49] uNDs at 4 mg/ml were suspended in 
10 mM histidine, 10% (w/v) sucrose, and 150 mM NaCl at pH 6, then point sonicated using the 
previously described conditions. RiVax stock (1.04 mg/ml) was thawed and 0.144 ml was diluted 
with 0.456 ml of histidine buffer for a final concentration of 0.25 mg/ml. From the RiVax 
working solution, 0.5 ml was added to 0.5 ml of the suspended nanodiamond solution for a final 
Rivax concentration of 0.125 mg/ml, which was then mixed by pipetting (5 times). The samples 
were stirred at ambient temperature, protected from light for 30 minutes to reach equilibrium 
binding. The Rivax/nanodiamond mixture was pipetted 5 times to resuspend any settled material 
and diluted to the injection concentration by removing 0.7 mL and adding 2.8 mL of diluent 
histidine buffer for a final Rivax concentration of 0.025 mg/ml. Before injection into the mice, 
the mixture was inverted to fully resuspend any sedimentation.  
 The mouse study was conducted at Wadsworth Center (Albany, NY) with female Swiss 
Webster mice that were 5-6 weeks in age (Taconic Labs, Hudson, NY). The vaccine was 
administered subcutaneously 40 and 19 days before challenge with a dose of 0.025 mg/ml of 
Rivax per mouse. Eleven days before the challenge, mice were bled from the lateral tail vein to 
17 
determine end point titers and neutralizing antibodies. Each mouse was challenged with ricin 
(10x lethal dose: ~2 ug/mouse)[48, 49] on day 0. The mice were then monitored for the next seven 
days for the onset of hypoglycemia. The glucose levels in the blood were determined with an 
ACCU-CHEK Aviva System blood glucose meter from Roche Diagnostics.[48] If the blood 
glucose levels dropped below 20 mg/dL, the mouse was euthanized.  
 The enzyme-linked immunosorbent assay (ELISA) microtiter studies were conducted at 
Taconic Labs (City, State) as previously described.[49, 57] Nunc Maxisorb F96 microtiter plates 
(Thermo Fisher Scientific, Miami, OK) were coated with ricin, (0.1 µg/well) in PBS (pH 7.4) 
and were incubated overnight at 4°C in a humidified chamber. The plates were washed three 
times with PBS-Tween 20 (PBS-T; 0.05%, v/v) and were blocked with goat serum (2%, v/v, in 
PBS-T) for 1 h at room temperature before being probed with mAbs or hybridoma supernatants 
diluted in mouse serum. For the ELISAs, horseradish peroxidase (HRP)-labeled goat anti-mouse 
IgG-specific polyclonal antibodies (SouthernBiotech) were used as the secondary reagents, and 
3,3′,5,5′-tetramethylbenzidine (TMB; Kirkegaard & Perry Labs, Gaithersburg, MD) was used as 
the colorimetric detection substrate. ELISA plates were analyzed with a SpectraMax 250 
spectrophotometer (Molecular Devices, Sunnyvale, CA), with Softmax Pro software (Molecular 
Devices version 5.2).  
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4. Results 
4.1. Nanodiamond Surface Chemical Modification 
 Different chemical modifications were made to the MSY monocrystalline diamond 
powder to optimize loading potential of a protein antigen onto the surface of the nanodiamonds. 
The four nanodiamond forms investigated were unmodified (uND), oxidized (oND), acidified 
(aND), and diamine modified (dND). Chemical modifications on the nanodiamonds’ surfaces 
were monitored by XPS to determine the chemical composition as demonstrated in Figure 2. The 
carbon peak (1s orbital carbons) was focused and separated into sp2 and sp3 hybridizations to 
determine the ratio of diamond carbon to graphitic carbon represented by 284.3 eV and 285.2 
eV, respectively.[58, 59] The ratio of the sp3 to sp2 decreased with further modification. uNDs 
contained the highest ratio at 1.93, indicating the greatest presence of sp3 hybridized carbons, 
and the dNDs contained the lowest ratio at 1.32. The oNDs had a sp3 to sp2 ratio of 1.75 and the 
aNDs ratio was 1.34. The oxygen peak around 535.5 eV had the highest intensity for the oNDs 
by a factor of 1.5 compared to the uNDs and aNDs, and a factor of 2 compared to the dNDs. The 
Figure 2. XPS spectrum resolution of carbon (C1) peak, oxygen (O1) peak, and nitrogen (N1) peak. The bulk surface 
composition for the unmodified, oxidized, acidified, and amine modified nanodiamonds were compared against each other in a 
stacked, overlaid view to compare the intensities correlated to the appropriate binding energy in electron volts (eV). 
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nitrogen peak appeared at 401 eV and was present only on the dNDs. The additional peaks in the 
dNDs were the sodium and chloride atoms from the PBS buffer.  
 Alteration of the nanodiamonds’ surface chemistry should induce changes in its surface 
potential indicative of various chemical functional groups. Each of the nanodiamond derivatives 
were suspended in 10 mM KCl at pH 4 and assessed for zeta potential. In Figure 3, changes 
observed in zeta potential between derivatives compared to uNDs were consistent with 
previously reported literature values.[45] The uNDs and aNDs had similar zeta potentials at -33.6 
mV, oNDs at -25.4 mV, whereas the dNDs at 10.5 mV for the 4 hour and  9.5 mV for 21 hour 
reaction time points. The 10 mM KCl, pH 4 buffer was selected due to the positive charge 
affirmation due to expected surface functional groups’ pKa values.[45] dNDs were measured at 
various times points to determine if there was any time dependent alteration in charge. No 
substantial changes were observed between the 4 hour and 21 hour time points.[60, 61] 
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Figure 3.  Surface chemical alterations were assessed by zeta potential at a concentration of 0.01 mg/ml for each nanodiamond 
derivative in 10 mM KCl, pH 4. Each sample (900 µL) was placed in a cuvette and scanned three times as a technical replicate.  
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 FTIR was used to determine the change in vibrational states as the IR radiation was 
absorbed by particular functional groups, demonstrated in Figure 4. The spectra were noisy due 
to low intensity signals from the instrument, but the peaks represented in the spectrum still 
articulate the differences between modifications. The uNDs contained a broad -OH stretching 
band around 3400 cm-1 from hydroxyls on the surface. Carboxylic anhydride stretching was 
present on the surface of the uNDs with C=O peak and C-O peak at 1790 cm-1 and 1200 cm-1, 
respectively.[62, 63] The oNDs had an increase in C-O bonds, a decrease in -OH bonds, and a 
decrease in the carboxylic anhydride stretching. The aNDs had an increase in -OH stretching and 
an increase in the carboxylic anhydride stretching compared to uNDs. The dNDs have amide 
bands represented at 1665 cm-1, 1550 cm-1, and 1217-1317 cm-1. Additional peaks confirming 
amines were represented between 3050-3450 cm-1 for NH2 stretching/bending vibrations and NH 
stretching at 1630 cm-1.[3, 64] The two peaks at 2800 cm-1 and 3000 cm-1 are the sp2 and sp3 
hybridizations for CHx atoms.[65] 
Figure 4. FTIR spectra of dry ND powders intensity were normalized and staggered to compare 
peak positions between derivatives. 
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 Raman spectroscopy was used to further characterize surface modifications between 
different physical and chemical treatments of the ND powder. The ramen spectra represented in 
Figure 5A depicts the carbon peak at 1330 cm-1 and the D-band —the disorder of the sp2 hybrid 
carbons —at 1420 cm-1.[45, 66] After deconvolution and integration of the Raman spectrum, the 
crystal lattice structure and D-band-associated peaks were assessed to quantify the difference 
between modifications as shown in Figure 5B. Throughout progressive modifications, the carbon 
peak decreased, which was attributed to the various functional groups representing a larger 
percentage of the overall surface. The D-band decreased in the oxidation and acidification 
modifications indicating a decrease in graphene on the surface. [67] 
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Figure 5. (A) Normalized raman spectra of nanodiamond derivatives at 0.1 mg/ml in 10 mM KCl. (B) Deconvolution and 
integration of 1330 cm-1 and 1420 cm-1 peaks of spectra were performed in Peakfit program.  
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4.2. Nanodiamond Sizing and Morphology 
 The hydrodynamic radius was measured using DLS to determine if any of the alterations 
made on the nanodiamonds altered their particle size. In Figure 6, the hydrodynamic radii of the 
derivatives were measured while suspended in 10 mM KCl at pH 4. The uNDs were measured to 
have a radius of 37 nm. The oNDs had an increased radius of 51 nm and the aNDs radius was 
similar to the uNDs at 36 nm. The dNDs had a significant increase in radius but this was deemed 
inconclusive due to the high sedimentation and high self-aggregation of dNDs.  
 TEM with an electron dispersive X-ray attachment was used to provide a compositional 
analysis and to observe crystalline morphology for each of the derivatives shown in Figure 7. 
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Figure 7. TEM samples were suspended in ethanol at 1mg/ml and examined within a polymeric scaffold. Three different 
nanodiamond clusters were examine on the scaffold and averaged to display compositional analysis.  
Figure 6. The hydrodynamic radius of ND derivatives verified using DLS and compared against the polystyrene microsphere 
standards. Measurements were made with 6 replicates of 5 acquisitions each.  
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The carbon peak at 274 eV was highest for the uNDs at 1593 counts, while the aNDs was the 
smallest at 713 counts. The oxygen peak represented at 532 eV and the nitrogen peak represented 
at 525 eV, where both slightly increased on the aNDs at 39 counts and 41 counts compared to the 
oNDs at 73 counts and 62 counts, respectively. Peaks present at sodium, 1044 eV, and chloride, 
2612 eV, associated positions suggest residual PBS buffer remaining following the dND 
synthesis. 
 The TEM was also used to view the surface of each of the nanodiamond derivatives to 
determine size and the crystal lattice integrity. Granular structures were present in all images. 
When magnified vertical lines were present, this suggests lattice fractures in the structure.[68] The 
unorganized lines were either amorphous carbons or graphitically bonded glassy carbons.[69] 
Figures 8A and 8B are representative images used to examine the uNDs for size and crystal 
lattice integrity. Similar images are shown for oNDs (8C and 8D), aNDs (8E and 8F), and dNDs 
(8G and 8H). 
Figure 8. TEM images of the nanodiamonds in clusters on the polymeric scaffold. Crystallinity and amorphous carbons were 
also observed in the right column to determine the amount of graphene still present.   
A B 
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4.3. Antigens on Nanodiamond associated Binding Isotherms  
 Two different protein antigens were selected to evaluate the loading capacity of the 
surface of the nanodiamond derivatives as shown in Figure 9. The model protein antigens chosen 
were bovine serum albumin (BSA) and lysozyme due to their opposite anionic and cationic 
charges at pH 7, respectively.[70] Of note, BSA isoelectric point is around 4 and Lysozyme 11. 
Figures 9A and 9D demonstrate the binding isotherms of BSA and Lysozyme, respectively at a 
constant amount (1 mg/ml) of nanodiamond. All modified nanodiamonds had no substantial 
change with increasing BSA concentration, except uNDs where maximized saturation of BSA 
occurred at 1 mg/ml. For lysozyme, no substantial difference in binding capacity was observed 
between the nanodiamonds except for dNDs at 0.5 mg/ml, which only bound 1/4 the capacity of 
other derivatives. [71, 72] 
 Figures 9B and 9E illustrates the dependence of normalized protein adsorption on ND 
concentration. BSA and lysozyme concentrations were kept constant at 0.5 mg/ml. The 
F 
Figure 9. Binding isotherms for two model proteins, BSA (top) and lysozyme (bottom). Three separate binding isotherm variations 
were used varying the protein antigen concentration (left), varying the concentration of ND (middle) and varying the pH (right). 
Nanodiamond variants: unmodified (blue), oxidized (red), acidified (green), and amine addition (purple+ orange). Each sample 
mixed for 30 minutes prior to centrifugation to separate bound and unbound antigen. Three replicates were made for the 
concentration variations and six replicates for pH variations. 
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concentration of nanodiamonds selected were 1, 0.5, 0.25, and 0.125 mg/ml for the BSA trials 
and 2, 1, 0.5, and 0.25 mg/ml for lysozyme. BSA had similar binding capacities for all 
nanodiamond derivatives except dNDs where no further BSA was adsorbed with increasing 
concentration of dNDs.   
 Figures 9C and 9F demonstrate the effects of altered pH on protein adsorption to the 
nanodiamond derivatives. For all anionic nanodiamonds; uNDs, oNDs, and aNDs, more BSA 
was adsorbed at lower pH when BSA was more cationic. dNDs did not have a significant change 
in binding capacity as pH became more alkaline. For lysozyme, all nanodiamonds adsorbed a 
constant amount of protein as the pH became more alkaline, except for uNDs. uND lysozyme 
adsorption increased as pH became more alkaline.  
 After initial binding isotherm assays, the uNDs were selected as the lead candidate for 
RiVax vaccine binding due to its high binding capacity, optimal size, and manufacturing 
simplicity for both model proteins. To understand the binding capacity of RiVax on the surface 
of the uNDs, various concentrations of RiVax were tested to demonstrate the saturation point of 
RiVax adsorbed to the nanodiamonds. The concentration of nanodiamonds were held constant at 
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Figure 10. RiVax nanodiamond adsorption isotherms following a mixing time of 2.5 hours. The blue line (10 mM Histidine, 10% 
sucrose, and 150 mM NaCl) and the red line (10 mM Histidine and 10% Sucrose) at pH 6 with three replicates in each buffer. 
Data fit using a one-phase decay model with error bars representing ± SD. 
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2 mg/ml. At 0.5 mg/ml of RiVax in solution, 1380 ug of RiVax adsorbed to the surface for every 
miligram of uND as shown in Figure 10.  Two different solutions were tested due to the extreme 
sedimentation of the nanodiamonds in the 10 mM Histidine, 10% Sucrose, and 150 mM NaCl 
buffer. Without 150 mM NaCl in the buffer, the rate of sedimentation at 4°C took 7 days longer. 
The salt containing buffer was selected to move forward regardless of the sedimentation risks to 
maintain isotonic conditions. 
 
4.4. Nanodiamond Bound RiVax Structural Integrity 
 The intrinsic tryptophan fluorescence of RiVax was monitored over increasing 
temperatures (Figure 11) to determine the protein’s melting temperature, the temperature at 
which its tertiary structure begins to denature. uND bound RiVax (Figure 11B) or RiVax alone 
(Figure 11A) in increasing concentrations (0.01 to 0.5 mg/ml) were suspended in 10 mM 
Histidine, 10% Sucrose, and 150 mM NaCl. Intrinsic fluorescence lifetime was measured from 
10 °C to 95 °C. The melting temperature was determined by plotting the lifetime moment versus 
the temperature and taking the first derivative. Average melting temperature results (n=6) were 
54.62 °C, 64.62 °C, 55.98 °C, 57.35 °C, and 58.71 °C for uND + RiVax in descending 
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Figure 11. Intrinsic tryptophan lifetime fluorescence melts for (A) RiVax and (B) RiVax + ND. Each of the samples (n = 6) were 
suspended in 10 mM Histidine, 10%  (w/v) Sucrose, and 150 mM NaCl at pH 6. 
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concentrations and 55.98 °C, 54.62 °C, 55.98 °C, 55.98 °C, and 57.35 °C for RiVax in 
descending concentrations. There was a slight positive shift in the intrinsic tryptophan 
fluorescence with uND + RiVax, which demonstrated a difference in the tertiary structure of the 
protein. [73] 
 FTIR was used to assess the secondary structure of RiVax when bound to the 
nanodaimonds surface. Following the deconvolution of the second derivative of the amide I 
region, structural contributions to the overall secondary structure were assessed based on 
previously reported spectral designations shown in Figure 12.[77] The peaks between 1600 nm 
and 1640 nm represent the beta sheets of the secondary structure, peaks 1650 nm to 1660 nm 





















P e r c e n t P e a k  A re a  o f W h o le
R ivax
R iva x  on  N D
Figure 12. The secondary derivative of each FTIR spectra was deconvoluted to determine the relative contributions to 
the overall secondary structure for nanodiamond bound (left) and free (right) RiVax. Peak area contributions to the 
overall spectral area for each condition are plotted below.   
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represent the alpha helical structures, and peaks around 1680 nm represent the beta turns. RiVax 
consisted of 0.43 alpha helix, 0.43 beta sheets, and 0.14 beta turn, while RiVax on the surface of 
the nanodiamonds were 0.48 alpha helix, 0.27 beta sheet, and 0.25 beta turns. Secondary 
structure variations are present especially in the beta turn and beta sheet structures, which 
suggests changes in RiVax’s secondary structure when adsorbed to uNDs.   
 
4.5. Nanodiamond Bound RiVax Antigencity  
  Biolayer interferometry was used to quanitify antibody associaiton with uND bound 
RiVax. From previous studies, RiVax’s neautralizing antibodies PB10, LE4, JD4,WECH, and 
CH1 were identified and isolated.[9] The monoclonal antibody LE4 was used for affinity 
comparison between RiVax and particle bound RiVax. Baseline corrected association and 
dissocation curves for both bound and free RiVax are seen in Figure 13. The dissocation rate was 
too inconsistent to accurately measure for either condition tested likely because of the high 
affinity between LE4 and RiVax. With increasing concentraiton for both conditions, the on rate 
increased.[74] 
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Figure 13. BLI kinetics was analyzed with LE4 at 0.05 mg/ml as the antibody and anti-mouse tips for the FAB region. Each 
on rate onto the tips was compared at various concentrations of RiVax and buffer conditions. The off rate was neglected due 
to the slow desorption off the tips.  
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4.6. Nanodiamond Bound RiVax in vivo Response  
 The quanitified antibody association when RiVax bound to uNDs warrented an in vivo 
nanodiamand vaccine study using a relevant mouse model. Six mice were used for each 
vaccination group (RiVax and RiVax + uND). Forty days prior to challenge with soluble ricin, 
the two vaccines were given to each dosing group. Mice were boosted three weeks later with an 
equivalent does, and bled eight days priod to challenge to determine antibody titers. Mice were 
challenged with 2 µg ricin and monitored for 7 days. Figures 14A and 14B represent the serum 
dilutions tested on plates coated with ricin holotoxin in terms of absorbed light at 450 nm. uND 
bound Rivax immunized mouse 1, 2 and 5 sera showed low recognition of adsorbed ricin 
indicated by the insufficient amount of toxin-neutralizing titers. Figures 14C and 14D tested cell 
viability of soluble ricin, which was extremely low in all mice compared to tradition RiVax. 
Neturalizing end-point (EP) titers of mice dosed with RiVax + uNDs and RiVax + Alum can be 
viewed in Figures 14E and 14F. Stark decrease in polyclonal antibody (pAb) binding to soluble 
ricin versus bound ricin holotoxin are seen in the RiVax + uND immunization group.  
 After all mice were confirmed to have sufficient EP titers, each mouse was given a lethal 
dose challenge and monitored for effects. Of the six mice dosed in the RiVax + uND group, three 
with low EP titers died within 3 days time, while the other three survived until study termination 
on day 7. The three mice that survived also had signs of morbidity, such as ruffle, hunch, 
weakness, and tremors that improved over 7 days. No signs of morbitiy occurred on days 5-7. 
The mice in the RiVax, RiVax + Alum, and RiVax + AuNP immunization groups all lived and 





Figure 14. The ricin challenge model in 6 mice for a 2 ug/mouse dose (10x LD50), where the pre-challenge 
end point binding curves for ricin holotoxin were compared between (A) RiVax and (B) RiVax + uND. The 
serum was diluted on plates to determine the specific end point titer values for the IC50 for (C) RiVax 
compared to (D) RiVax + uND on the nanodiamonds. Since there were no significant amount of neutralizing 
antibodies produced by RiVax + uND vaccine, EP titers were determined on captured soluble ricin and non-
native ricin, where (E) RiVax+Alum was used as the control to compare to the (F) nanodiamond vaccine. The 









 Nanoparticulate delivery platforms that have tailorable physicochemical properties are of 
high interest for controlled delivery and presentation of subunit vaccine components. 
Nanodiamonds have easily controllable surface chemistry, which enables controlled adsorption 
of antigen to the surface. These complexes provide subunit presentation that mimics virus-like 
particles, potentially invoking an improved protective immunological response compared to 
subunit administration alone. In this study, nanodiamonds with varied surface chemistries were 
produced and characterized. Association studies with model proteins were performed to 
determine how these nanodiamond properties affect their binding capacity. The ricin subunit 
vaccine, RiVax, was used as a model subunit antigen for nanodiamond complexation in an 
adsorbed vaccine delivery model in hopes of improving RiVax’s efficacy as a potential ricin 
vaccine.  
 Oxidative, acidic, and basic chemical modifications were explored to change functional 
group presentation on the nanodiamond surface in an attempt to optimize binding of a protein 
antigen. The specific chemical alterations were assessed by XPS, zeta potential, raman, and 
FTIR. Clear representation of graphitic carbons was observed on the unmodified nanodiamonds 
with a broad D-band in the Raman spectrum and the sp2 peak at 3000 cm-1 in the FTIR spectrum. 
Extensive heating of the nanodiamonds results in covalent bonds between the carbon on the 
nanodiamond surface and ambient O2 present in the air. This process binds oxygen to the surface 
of the nanodiamonds, which explains the increase in C-O groups present at 1200 cm-1 peak 
observed on the oNDs. The reduction in the D-band confirms the calorimetric change in the 
oxidized nanodiamonds as the graphene layers disassociate. Acidification by a strong acidic bath 
etches sp2 orbitals, leading to a reduction in the D-band and a reduction in C-O bonds due to the 
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protonation of -COOH, -OH, -COH, etc. on the surface. Amination of the acidified 
nanodiamonds led to a significant N-H peak at 1100 cm-1 and a significant reduction in the D-
band. A limitation of FTIR spectroscopy is that a significant number of peaks were not present 
above 2500 cm-1, which could be attributed to the asymmetrical dipole moment that occurs with 
vibrations to produce FTIR peaks. If the bonds stretch or vibrate proportionally, the spectrum 
will not produce peaks due to lack of asymmetric change in the dipole moment. Raman should 
detect for symmetric changes, which is why we used these complimentary spectroscopy 
methods, but was used in this study to assess the D-band and diamond-carbon peak.  
 The surface charges from the zeta potential analysis for the unmodified, oxidized, and 
acidified nanodiamonds all support the FTIR and raman results by being highly negatively 
changed and can be attributed to unprotonated moities like -COOH, -OH, -COH. The amination 
surface charge also corresponds to the FTIR and Raman due to the positive charge from to the 
protonation of the amine groups.[75, 76]  
 The chemical compositions of the nanodiamonds were determined by the XPS analysis 
and confirmed the other surface chemistry characterization. A decrease in the sp2 hybridization 
throughout modification was present in the spectra and the weight percent composition of the 
nanodiamonds agreed with FTIR. The unmodified nanodiamonds contained primarily carbon as 
expected since diamond is purified carbon. The oxidized nanodiamonds had a significant amount 
of oxygen present as expected, as covalent carbon-oxygen bonds were produced on the surface at 
high temperatures. The acidified nanodiamonds had no significant changes in their elemental 
composition compared to the oxidized nanodiamonds. Lastly, the amination nanodiamonds had a 
significant amount of nitrogen present on the surface due to the incorporation of the polyamine 
spermine.   
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 Particle size was assessed by DLS to verify that no significant change had occurred due 
to modification of the nanodiamonds. The hydrodynamic radius for the unmodified 
nanodiamonds was 40 nm. The amine modified nanodiamonds had the widest size distribution 
spanning from 30 nm to 100 nm. As seen in the TEM, nanodiamonds appear in clusters and the 
wide size distribution observed in the data contributes to aggregation of the particles. TEM 
verified the crystallinity of the nanodiamonds, with vertical lines present in all images when 
magnified, contributing to the lattice spacing in the structure.[77] The lattice spacing confirms that 
sections of the nanodiamond contain diamond sp3 hybridized carbons, while the granular 
structures are either amorphous carbons or graphetically bonded glassy carbons.[69] Also, the 
TEM compositional spectra were in agreement with the XPS compositional spectra. 
 Analysis of the binding capacity of the nanodiamonds to protein antigen was assessed 
using the model proteins BSA and lysozyme by monitoring the unbound material in solution. 
Initially when the nanodiamond derivatives were formulated, it was hypothesized that a cationic 
surface, such as the dNDs, would have the highest binding capacity since most proteins are 
anionic in nature (including RiVax). However, over all conditions the amine modified adsorbed 
the least amount of protein compared to any of the other derivatives. With the BSA binding 
isotherm showing increasing bind and increasing pH, no distinct changes occurred for the amine 
modified due to two cationic forces repelling at acidic conditions and potentially continuing 
repulsion in forms of an anionic charge when the solution becomes more alkaline. However, for 
anionic nanodiamonds such as uNDs, oNDs, and aNDs, all nanodiamonds adsorbed higher 
amounts of BSA (pI 4) at acidic pH because BSA becomes cationic at pH 4. With varying pH, 
lysozyme (pI 11) becomes less cationic at high pH. The anionic nanodiamonds should decrease 
in binding capacity at alkaline conditions, which does not occur. The uNDs and oNDs increase in 
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capacity with more basic conditions, potentially caused by non-specific binding or hydrophobic 
binding as lysozyme becomes less charged. No significant changes are present in the aNDs and 
dNDs as the pH becomes more alkaline.  
  The high binding capacity of the unmodified nanodiamonds lead to their selection for 
RiVax complexation and characterization. The unmodified nanodiamonds adsorbed 1380 µg of 
RiVax/mg of nanodiamond, which was almost 14 times more than the amount used in human 
clinical trials.[51] Nanodiamonds are efficient in adsorbing RiVax to the surface at physiological 
pH.  
 Based on intrinsic tryptophan fluorescence data, the tertiary stability of RiVax had a 
higher stability on the surface of the nanodiamonds than alone suggested by the 3 °C increase in 
melting temperature. As the protein unfolds, new tryptophan residues, which are hydrophobic 
become exposed. These new tryptophan residues generate increased fluorescence as shown by a 
large increase in the spectrum. When the buffer quenches the new residues, a steady decrease in 
intensity proceeds as the protein denatures and is further quenched by buffer. Since the 
denaturing of the protein occurred at a higher temperature, a small improved stabilization was 
present when bound to the nanodiamonds. 
 Changes to the RiVax secondary structure were observed by FTIR, with changes in alpha 
helices, beta sheets, and beta turns that can be attributed to the increase in melting temperature. 
The FTIR spectrum was observed only at the amide I peak, since the C=O stretching vibrations 
coupled to the N-H bonds and stretching of C-N bonds are highly sensitivity to small 
variations.[78] Major difference occurred in the beta sheet and beta turn structures; a 16% 
reduction and 11% elevation, respectively, compared to RiVax in solution. Beta turns change the 
direction of the polypeptide chain, which may be significant in stabilizing the formation of 
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tertiary interactions.6 With a more stable secondary and tertiary structure, this could provide a 
longer shelf-life for the vaccine. 
 The affinity of RiVax + uND to LE4 antibody was assessed using BLI to quantify the 
rate of binding of a model anti-RiVax antibody to RiVax + uND. Of note, the dissociation was 
very minimal compared to the association rate, which was why the association rate, kon, was used 
to measure affinity rather than the binding constant. As the concentration of RiVax increased the 
on-rate increased. In addition, non-specific binding was not present because no association was 
present with nanodiamond controls. A key conclusion was that when RiVax was bound to the 
nanodiamonds, the antigen is still recognized by antibody. 
 In the in vivo study, the holotoxin ricin was bound to a plate and coated with each 
mouse’s serum. In the RiVax+uND dosing group, three mice had significant recognition of 
bound ricin, two had a moderate amount, and one had no recgonition of the toxin. Animal sera 
were then assesed for the amount of neutralization that occurred to soluble ricin. All antibodies 
produced in the RiVax+uND group had very minimal recognition to soluble ricin. Furthermore, 
the changes in structure of RiVax on the surface of the nanodiamond are sufficient that the Abs 
are not very cross-reactive to the soluble ricin. The kill curve of the mice study found that three 
mice died over a three-day timespan, while the RiVax alone immuniation group had no deaths. 
As seen in the comparision between RiVax on Alum and RiVax+uND, all mice in the Alum 
group had a suffient amount of recgonition and neutralization to adsorbed and soluble ricin. 
Since the nanodiamond subgroup had 3 mice that only had a sufficient amount of recognition to 
adsorbed ricin, three mice lived. To note, a group made of RiVax on liposomes also had three 
mice die but all mice made large amounts of adsorbed ricin and soluble ricin antibodies. Our 
RiVax+uND vaccine has potential but does not produce a strong enough immune repsonse to 
37 
neutralize the toxin compared to other, more commonly used adjuvent strategies. Further work 
will be necessary to achieve this goal. 
 
6. Conclusion 
 Novel nanoparticulate vaccine platforms that are capable of providing a memory 
response in the body to viruses and toxins are being extensively studied. Nanodiamonds as a 
vaccine delivery platform have significant potential for surface manipulation and morphology 
that permits a wide application of possibilities. The nanodiamonds can bind antigenic material to 
the surface but alters the function of RiVax since the uNDs did not recognize soluble ricin. 
However, in the case of RiVax this is not the most suitable option as antibodies produced by the 
animals had insufficient recognition of soluble ricin. Overall, these results demonstrate that 
nanodiamonds can be used as a vaccine adjuvant but does not currently provide the best solution 
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